Taysha director receives RSU and option grants

Taysha Gene Therapies director Alison S. Long reported equity compensation awards.

Rhea-AI Filing Summary

Taysha Gene Therapies director Alison S. Long reported equity compensation awards. She received 21,335 shares of Common Stock as a restricted stock unit (RSU) award that will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, contingent on her continued board service.

She was also granted stock options covering 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, she directly holds 127,178 shares of Common Stock and 42,671 stock options.

Insider Trade Summary

Grant/Award: 64,006 shares

Grant/Award 2 txns

Insider Long Alison S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	42,671	$0.00	$0.00
Grant/Award	Common Stock	21,335	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 42,671 contracts (Direct); Common Stock — 127,178 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
2. F2. The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Key Figures

RSU award: 21,335 shares Stock options granted: 42,671 options Option exercise price: $5.97 per share +1 more

4 metrics

RSU award 21,335 shares Restricted stock units vesting by June 1, 2027 or next annual meeting

Stock options granted 42,671 options Right to buy common stock, vesting on same schedule as RSUs

Option exercise price $5.97 per share Exercise price for 42,671 stock options expiring June 1, 2036

Shares held after transaction 127,178 shares Total common stock directly owned after reported awards

Key Terms

restricted stock unit ("RSU"), Stock Option (right to buy), annual stockholders meeting, exercise price

4 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award."

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of $5.9700."

annual stockholders meeting financial

"vest on the earlier of June 1, 2027 or the next annual stockholders meeting"

exercise price financial

"conversion_or_exercise_price": "5.9700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Taysha Gene Therapies (TSHA) director Alison S. Long report on this Form 4?

Alison S. Long reported equity compensation awards from Taysha Gene Therapies, including a grant of RSUs and stock options. These awards increase her direct ownership in the company’s common stock and reflect routine director compensation rather than open‑market buying or selling activity.

How many RSUs did Alison S. Long receive from Taysha Gene Therapies (TSHA)?

She received an award of 21,335 restricted stock units (RSUs). These RSUs represent the right to receive an equivalent number of Taysha Gene Therapies common shares, subject to vesting conditions tied to her continued service on the company’s board of directors.

When do Alison S. Long’s RSUs and options in Taysha Gene Therapies (TSHA) vest?

Both the RSU award and the underlying shares for the stock options vest on the earlier of June 1, 2027 or the next annual stockholders meeting. Vesting is conditioned on Alison S. Long continuing to serve as a director through the applicable vesting date.

What are the terms of the stock options granted to Alison S. Long by Taysha Gene Therapies (TSHA)?

She received stock options for 42,671 shares of common stock with an exercise price of $5.97 per share. These options expire on June 1, 2036 and vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to continued board service.

How many Taysha Gene Therapies (TSHA) shares does Alison S. Long hold after these grants?

After the reported equity awards, Alison S. Long directly holds 127,178 shares of Taysha Gene Therapies common stock. She also holds 42,671 stock options, providing potential additional share ownership if exercised in the future under the option terms.

Is Alison S. Long’s Form 4 for Taysha Gene Therapies (TSHA) an open-market purchase or sale?

No, the Form 4 reflects equity compensation, not open‑market trades. The transactions are coded as grants or awards, meaning the RSUs and stock options were issued by Taysha Gene Therapies as part of director compensation rather than being bought or sold on the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Long Alison S

(Last) (First) (Middle)

C/O TAYSHA GENE THERAPIES, INC.

3000 PEGASUS PARK DRIVE, SUITE 1430

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Taysha Gene Therapies, Inc. [ TSHA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		A		21,335(1)	A	$0	127,178	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.97	06/01/2026		A		42,671		(2)	06/01/2036	Common Stock	42,671	$0	42,671	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

2. The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

	/s/ Kamran Alam, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)